MP50-07 CURRENT EVIDENCE DOES NOT SUPPORT THE HYPOTHESIS THAT STATIN USE REDUCES THE RISK OF PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Advanced (including Drug Therapy) II1 Apr 2016MP50-07 CURRENT EVIDENCE DOES NOT SUPPORT THE HYPOTHESIS THAT STATIN USE REDUCES THE RISK OF PROSTATE CANCER Ping Tan, Lu Yang, Shiyou Wei, Liang Gao, Zhuang Tang, and Qiang Wei Ping TanPing Tan More articles by this author , Lu YangLu Yang More articles by this author , Shiyou WeiShiyou Wei More articles by this author , Liang GaoLiang Gao More articles by this author , Zhuang TangZhuang Tang More articles by this author , and Qiang WeiQiang Wei More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.441AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are the most widely used drugs for lowering cholesterol. Recently, there has been increasingly great interest in the anti-tumor effects of statins, which have been shown to promote cancer cell apoptosis, inhibiting inflammation, tumor growth and invasion/metastasis. However, clinical studies have not yet shown a consensus. In this abstract, we aim to investigate the effects of statins use on prostate cancer (PCa) risk. METHODS We performed a literature search without language restrictions using the databases of PubMed, MEDLINE, EMBASE, The Cochrane Library, Web of Science, and ClinicalTrials.gov. Data from each study were independently extracted by two reviewers (TP and WSY). Odds Ratio (ORs) and their 95% CIs were used to assess the strength of association between statin use and the risk of PCa. Statistic heterogeneity scores were assessed with the standard Cochran's Q test. Publication bias was detected using the Egger's tests. Statistical significance was determined using the two-tailed test, where P < 0.05 was considered significant. STATA version 10 (Stata corporation, college station, TX) was employed to conduct all statistical analyses. RESULTS 8633 articles were identified initially, and after employing exclusion criteria, 42 studies were included in the meta-analysis. The pooled result suggested that statins had a neutral effect on total PCa (OR = 0.92 95% CI: 0.82-1.03). In addition, results showed that long-term statins use (n=14) (defined as ≥5 years of use) had no effect on the risk of PCa (OR = 0.86, 95% CI: 0.63-1.09). However, a 12% reduction in total PCa risk among in short-term statins users (n=14) (defined as <5 years of use) as compared to non-users was observed (OR = 0.88, 95% CI: 0.78-0.98). Furthermore, a plausible link was found between a decreased risk of advanced PCa (n=11) (defined by the stage of the disease as ′regional′ or ′distant′ or the TNM stage within T3-4, N1-3 and M1) and statins use (OR = 0.83, 95% CI: 0.75-0.92), which was the same as that in high-grade PCa (n=15) (defined as Gleason sum ≥ 7) (OR = 0.83, 95% CI: 0.66-0.99). However, the pooled results showed that use of any statin had a neutral influence on the occurrence of both low-grade PCa (defined as Gleason sum < 7) (OR = 0.95, 95% CI: 0.88-1.02) and localized PCa(defined by the stage of the disease as ′localized′ or the TNM stage as T1-2, N0/x and M0/x.) (OR = 0.98, 95% CI: 0.91-1.06). There was no publication bias observed (Egger's test, p=0.298) CONCLUSIONS The evidence determined by the analyses does not support the hypothesis that statins use are protective against the development of total prostate cancer, localized PCa and low-grade PCa. In addition, results show that long-term statins use has no effect on the risk of PCa. Instead, Statins use are associated with a protective effect for advanced prostate cancer and high-grade prostate cancer, however, which should be evaluated with caution, given the detection bias in these observational studies. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e675 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Ping Tan More articles by this author Lu Yang More articles by this author Shiyou Wei More articles by this author Liang Gao More articles by this author Zhuang Tang More articles by this author Qiang Wei More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...